Aldeyra Therapeutics, Inc. (ALDX) Analysts See $-0.32 EPS

February 24, 2018 - By Peter Erickson

 Aldeyra Therapeutics, Inc. (ALDX) Analysts See $ 0.32 EPS
Investors sentiment increased to 3.13 in Q3 2017. Its up 1.46, from 1.67 in 2017Q2. It improved, as 3 investors sold Aldeyra Therapeutics, Inc. shares while 5 reduced holdings. 11 funds opened positions while 14 raised stakes. 18.26 million shares or 145.50% more from 7.44 million shares in 2017Q2 were reported.
Millennium Ltd stated it has 545,085 shares. 683 Management Limited accumulated 835,514 shares. Moreover, Ardsley Advisory has 0.04% invested in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Ellington Mngmt Grp Inc Ltd Liability Corporation has invested 0.03% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Adage Cap Prns Gp Lc accumulated 0.01% or 750,000 shares. Geode Capital Limited Company stated it has 0% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). 7,500 are held by Natl Bank Of America Corp De. 1,364 are owned by Prelude Cap Mngmt Lc. Deutsche National Bank & Trust Ag invested in 0% or 8,000 shares. Knoll Cap Management L P reported 0.76% stake. Hikari Power Limited reported 0.1% stake. Vanguard Grp Incorporated invested in 0% or 471,031 shares. Barclays Public Limited Co accumulated 3,400 shares or 0% of the stock. Royal Savings Bank Of Canada holds 0% or 9 shares in its portfolio. Illinois-based Drw Secs Limited Liability has invested 0.03% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX).

Since September 19, 2017, it had 1 insider purchase, and 0 selling transactions for $1.45 million activity.

Analysts expect Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) to report $-0.32 EPS on March, 29.They anticipate $0.04 EPS change or 11.11 % from last quarter’s $-0.36 EPS. After having $-0.32 EPS previously, Aldeyra Therapeutics, Inc.’s analysts see 0.00 % EPS growth. The stock increased 2.03% or $0.15 during the last trading session, reaching $7.6. About 93,455 shares traded. Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) has declined 18.94% since February 24, 2017 and is downtrending. It has underperformed by 35.64% the S&P500.

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Ratings Coverage

Among 6 analysts covering Aldeyra Therapeutics Inc (NASDAQ:ALDX), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aldeyra Therapeutics Inc had 13 analyst reports since August 13, 2015 according to SRatingsIntel. The rating was maintained by Cowen & Co on Wednesday, August 9 with “Buy”. Canaccord Genuity maintained the stock with “Buy” rating in Wednesday, June 14 report. Stifel Nicolaus initiated the stock with “Buy” rating in Friday, July 1 report. The rating was maintained by H.C. Wainwright on Wednesday, August 9 with “Buy”. The firm has “Buy” rating given on Thursday, September 14 by Cowen & Co. The stock has “Buy” rating by Cantor Fitzgerald on Thursday, November 9. The stock of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) has “Buy” rating given on Tuesday, October 24 by Cantor Fitzgerald. On Monday, September 26 the stock rating was initiated by H.C. Wainwright with “Buy”. Cowen & Co initiated the shares of ALDX in report on Tuesday, September 8 with “Outperform” rating. The stock has “Buy” rating by H.C. Wainwright on Thursday, June 15.

Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. The company has market cap of $145.30 million. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency. It currently has negative earnings. The firm was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014.

More notable recent Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) news were published by: which released: “This ROTY Pilot Position Has Several Reasons To Run Higher” on February 22, 2018, also with their article: “Aldeyra Therapeutics Selected for Podium Presentation of Phase 2a Dry Eye …” published on February 21, 2018, published: “Aldeyra Therapeutics Announces Presentation of Results on the Efficacy of ADX …” on October 25, 2017. More interesting news about Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) were released by: and their article: “What’s Next For Aldeyra Therapeutics?” published on February 02, 2018 as well as‘s news article titled: “Aldeyra Therapeutics’ stock soars after positive results of dry eye disease …” with publication date: September 12, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.